.webp&w=384&q=75){kind=logo}
Loading, please wait...
Loading, please wait...
Abbott recently introduced the ICRAS Tool for Diabetes to assist Indian healthcare professionals in managing Type 2 Diabetes Mellitus (T2DM). This innovative web-based resource focuses on the early identification of heart and kidney complications. Consequently, clinicians can now assess risks more accurately during routine consultations. Since India has over 101 million people living with diabetes, such digital interventions are becoming vital for population health management. This tool aims to transform how doctors approach long-term complications by providing a data-driven framework for early intervention.
The ICRAS Tool for Diabetes integrates key medical test results and lifestyle factors to generate specific risk scores. Specifically, it evaluates the likelihood of a patient developing Diabetic Kidney Disease (DKD) and Coronary Heart Disease (CHD). Furthermore, the tool helps predict Major Adverse Cardiovascular Events (MACE) in individuals with T2DM. Because the platform accounts for gender-specific differences, it offers a more personalized summary of each patient's health status. Moreover, the developers designed the tool with privacy at its core. It does not capture personal information about patients or doctors, ensuring all assessments remain fully secure.
Heart and kidney conditions represent the most common and serious complications of Type 2 diabetes. For instance, nearly 40% of patients with T2DM suffer from chronic kidney disease. Additionally, one-third of individuals with diabetes face some form of heart-related issue. Many of these complications develop silently, meaning patients may feel fine while damage is already occurring. Therefore, early stratification allows doctors to tailor care in meaningful ways. Timely interventions can slow or even prevent serious complications, helping patients stay healthier for longer periods. By using evidence-based practice, clinicians can strengthen their overall patient evaluation process.
Q1: What specific conditions does the ICRAS Tool help identify?
The tool generates risk scores for Diabetic Kidney Disease (DKD), Coronary Heart Disease (CHD), and Major Adverse Cardiovascular Events (MACE) in people living with Type 2 Diabetes.
Q2: Is the ICRAS Tool accessible to all doctors in India?
Yes, it is a web-based tool designed to help clinicians across the country perform early cardio-renal risk assessment and stratification for their T2DM patients.
Q3: Does the tool require the input of personal patient identifiers?
No, the tool is designed to be privacy-secure and does not capture or store personal information about either the patient or the healthcare professional.
Disclaimer: This content is for informational and educational purposes only. It does not constitute medical advice or replace professional judgment. Refer to the latest local and national guidelines for clinical practice.
References
Read summarized clinical updates, watch expert medical content, and earn CME certifications right from your smartphone.
Open your smartphone camera to scan and install.
Abbott launches the ICRAS Tool to help Indian doctors identify early heart and kidney risks in Type 2 Diabetes patients, improving long-term clinical outcom...
7 months ago
Review how tailored exercise programs benefit frail older patients with heart failure. Explore pathophysiological mechanisms, individualized training prescriptions, and strategies to overcome adherence barriers in clinical practice.
Today
Recent clinical studies reveal maternal autoantibodies targeting IL-1RA as potential triggers for preterm labor, opening avenues for targeted cytokine therapies. Concurrently, new perioperative findings show inhaled cannabis increases propofol requirements during upper endoscopy compared to oral edible consumption.
Today
In high-risk pulmonary embolism complicated by severe anemia and active uterine bleeding, systemic thrombolysis is contraindicated. Large-bore aspiration thrombectomy provides rapid hemodynamic rescue without fibrinolysis, supported by inferior vena cava filter placement and multidisciplinary critical care.
Today
This comparative study evaluates posterior labral tears with and without glenohumeral instability, highlighting distinct demographic patterns, MRI underestimation in stable shoulders, and successful arthroscopic repair outcomes.
Today
A clinical study demonstrates that early intervention with tocilizumab, either as monotherapy or bridged with corticosteroids, achieves significant proptosis reduction and resolves active inflammation in treatment-naive thyroid eye disease.
Today
